Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGCT1531 active surveillance and carboplatin versus cisplatin study in low-risk and standard-risk germ cell tumors
jRCTs031180410Phase 3Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carboplatin, cisplatin, etoposide and bleomycin in germ cell tumor (GCT), immature ovarian teratoma (IOT) and Germ Cell Carcinoma (5 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Overall survival in low-risk malignant germ cell tumor cohort, Overall survival in ovarian pure immature teratoma cohort and 3 more. Started May 2020; status: recruiting.
02
Drugs
carboplatincisplatinetoposidebleomycin
03
Conditions
germ cell tumor (GCT)immature ovarian teratoma (IOT)Germ Cell Carcinoma
Beyond the preview
Go deeper on jRCTs031180410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180410.